조지아의 삼중음성 유방암 임상 시험
삼중음성 유방암 관련 연구 26개가 조지아 내 여러 지역에서 참여자를 모집하고 있습니다.
조지아의 도시
공식 연구 텍스트(영어)
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Emory University, Atlanta
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT06465069A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Winship Cancer Institute of Emory University, Atlanta
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT06270706A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Emory Winship Cancer Institute, Atlanta
- Augusta University, Augusta
피험자 모집 중1상
19세 이상 · 모든 성별 · 2026. 10. 1. 업데이트됨 · NCT06586957A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- City of Hope Cancer Center - Atlanta ( Site 0102), Newnan
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT06966700A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- University Cancer & Blood Center, LLC ( Site 0023), Athens
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT06841354Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- University Cancer & Blood Center, LLC., Athens
- Piedmont Cancer Institute, Atlanta
- Northside Hospital, Atlanta
- 외 3개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 9. 업데이트됨 · NCT05633654A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
- Emory University (Data Collection Only), Atlanta
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 9. 업데이트됨 · NCT05570253A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- Emory University, Atlanta
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 4. 업데이트됨 · NCT06400472Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
- Emory University, Atlanta
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 3. 업데이트됨 · NCT05846789ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
- Emory University Winship Cancer Institute, Atlanta
- Winship Cancer Institute of Emory University, Atlanta
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 8. 31. 업데이트됨 · NCT06460298A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Northside Hospital, Atlanta
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 8. 10. 업데이트됨 · NCT06926868Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Augusta University Georgia Cancer Center, Augusta
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 8. 4. 업데이트됨 · NCT05579366A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- University Cancer & Blood Center, Athens
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 7. 28. 업데이트됨 · NCT06150664A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Winship Cancer Institute, Emory University, Atlanta
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 6. 29. 업데이트됨 · NCT05377996Study of XB010 in Subjects With Solid Tumors
- Winship Cancer Institute, Atlanta
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 6. 22. 업데이트됨 · NCT06545331BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
- Winship Cancer Institute / Emory University, Atlanta
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 6. 15. 업데이트됨 · NCT05768932Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer
- Emory University Hospital, Atlanta
피험자 모집 중2상
18세 이상 · 여성 · 2026. 6. 4. 업데이트됨 · NCT05741164A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- Georgia Cancer Center, Augusta
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 6. 4. 업데이트됨 · NCT04300556Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab
- Emory University/Winship Cancer Institute, Atlanta
피험자 모집 중관찰 연구건강한 지원자 환영
18세 이상 · 여성 · 2026. 5. 7. 업데이트됨 · NCT05877859I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Winship Cancer Institute of Emory University, Atlanta
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 5. 6. 업데이트됨 · NCT01042379High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer
- Emory University Hospital/Winship Cancer Institute, Atlanta
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 4. 17. 업데이트됨 · NCT06492759Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
- Emory University, Winship Cancer Institute, Atlanta
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 2. 25. 업데이트됨 · NCT02926690A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
- Winship Cancer Institute - Emory University, Atlanta
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 1. 30. 업데이트됨 · NCT06926920Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
- Grady Health System, Atlanta
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- 외 1개
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 1. 26. 업데이트됨 · NCT06324240A Beta-only IL-2 ImmunoTherapY Study
- Emory - Winship Cancer Institute, Atlanta
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2025. 7. 9. 업데이트됨 · NCT05086692A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
- Columbus Regional Research Institute, LLC, Columbus
피험자 모집 중3상
18세 ~ 65세 · 여성 · 2025. 3. 21. 업데이트됨 · NCT03671044ClinicalTrials.gov 출처, 2026. 10. 5. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.